Autologe hämatopoetische Stammzelltransplantation bei Autoimmunerkrankungen

ZUSAMMENFASSUNG

Die Stammzelltransplantation von hämatopoetischen Stammzellen (HSCT) kann den autoaggressiven Teil des Immunsystems ersetzen. Daher stellt diese Therapie eine Option auch für schwere Autoimmunerkrankungen dar. Vor allem bei der Systemischen Sklerose und der Multiplen Sklerose konnte durch prospektive, randomisierte Studien die Effektivität der Therapie gezeigt werden. Die hämatopoetische Stammzelltransplantation ist eine aggressive Therapie mit vielen möglichen Komplikationen, daher darf die Indikation nur durch erfahrene Zentren und bei gut ausgewählten Patienten erfolgen. Einige Studien laufen derzeit auch in Deutschland.

• Literatur

• 1 van den Broek T, Borghans JAM, van Wijk F. The full spectrum of human naive T cells. Nat Rev Immunol 2018; 18: 363-373
• 2 Delemarre EM, Roord ST, van den Broek T. et al Brief report: Autologous stem cell transplantation restores immune tolerance in experimental arthritis by renewal and modulation of the Teff cell compartment. Arthritis Rheumatol 2014; 66: 350-356
• 3 Farge D, Arruda LC, Brigant F. et al Long-term immune reconstitution and T cell repertoire analysis after autologous hematopoietic stem cell transplantation in systemic sclerosis patients. J Hematol Oncol 2017; 10: 21
• 4 Henes J, Glaeser L, Kotter I. et al Analysis of anti-topoisomerase I antibodies in patients with systemic sclerosis before and after autologous stem cell transplantation. Rheumatology (Oxford) 2017; 56: 451-456
• 5 Passweg JR, Baldomero H, Bader P. et al Is the use of unrelated donor transplantation leveling off in Europe? The, 2016 European Society for Blood and Marrow Transplant activity survey report. Bone Marrow Transplant 2018; 53: 1139-1148
• 6 Statkute L, Verda L, Oyama Y. et al Mobilization, harvesting and selection of peripheral blood stem cells in patients with autoimmune diseases undergoing autologous hematopoietic stem cell transplantation. Bone Marrow Transplant 2007; 39: 317-329
• 7 Blank N, Lisenko K, Pavel P. et al Low-dose cyclophosphamide effectively mobilizes peripheral blood stem cells in patients with autoimmune disease. Eur J Haematol 2016; 97: 78-82
• 8 Elhai M, Meune C, Boubaya M. et al Mapping and predicting mortality from systemic sclerosis. Ann Rheum Dis 2017; 76: 1897-1905
• 9 Kowal-Bielecka O, Fransen J, Avouac J. et al Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis 2017; 76: 1327-1339
• 10 Henes JC, Schmalzing M, Vogel W. et al Optimization of autologous stem cell transplantation for systemic sclerosis -- a single-center longterm experience in 26 patients with severe organ manifestations. J Rheumatol 2012; 39: 269-275
• 11 Burt RK, Shah SJ, Dill K. et al Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet 2011; 378: 498-506
• 12 van Laar JM, Farge D, Sont JK. et al Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA 2014; 311: 2490-2498
• 13 Sullivan KM, Goldmuntz EA, Keyes-Elstein L. et al Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma. N Engl J Med 2018; 378: 35-47
• 14 Sullivan KM, Majhail NS, Bredeson C. et al Systemic Sclerosis as an Indication for Autologous Hematopoietic Cell Transplantation: Position Statement from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2018; 24: 1961-1964
• 15 Mancardi GL, Sormani MP, Gualandi F. et al Autologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trial. Neurology 2015; 84: 981-988
• 16 Lindsay JO, Allez M, Clark M. et al Autologous stem-cell transplantation in treatment-refractory Crohn’s disease: an analysis of pooled data from the ASTIC trial. Lancet Gastroenterol Hepatol 2017; 2: 399-406
• 17 Brierley CK, Castilla-Llorente C, Labopin M. et al Autologous Haematopoietic Stem Cell Transplantation for Crohn’s Disease: A Retrospective Survey of Long-term Outcomes from the European Society for Blood and Marrow Transplantation. J Crohns Colitis 2018 May 18. doi: 10.1093/ecco-jcc/jjy069
• 18 Burt RK, Han X, Gozdziak P. et al Five year follow-up after autologous peripheral blood hematopoietic stem cell transplantation for refractory, chronic, corticosteroid-dependent systemic lupus erythematosus: effect of conditioning regimen on outcome. Bone Marrow Transplant 2018; 53: 692-700
• 19 Cao C, Wang M, Sun J. et al Autologous peripheral blood haematopoietic stem cell transplantation for systemic lupus erythematosus: the observation of long-term outcomes in a Chinese centre. Clin Exp Rheumatol 2017; 35: 500-507
• 20 Leng XM, Jiang Y, Zhou DB. et al Good outcome of severe lupus patients with high-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation: a 10-year follow-up study. Clin Exp Rheumatol 2017; 35: 494-499
• 21 Walicka M, Milczarczyk A, Snarski E. et al Lack of persistent remission following initial recovery in patients with type 1 diabetes treated with autologous peripheral blood stem cell transplantation. Diabetes Res Clin Pract 2018; 143: 357-363